Mylan has completed an 85,000 ft2, three-story expansion project at its transdermal patch facility in St. Albans, Vermont. The facility, operated by Mylan Technologies Inc. (MTI), is a subsidiary of Mylan that focuses on transdermal drug delivery. Mylan's investment includes expanded R&D capabilities and additional manufacturing and laboratory space. In addition, Mylan is in the process of adding more than 160 new positions to its St. Albans-based workforce.
The 14-month expansion project has increased MTI's total operating space to more than 391,000 ft2.